In an exclusive interview, Alterity Therapeutics’ ( ATHE) CEO David Stamler met with The Fly to discuss the company, the biotech industry, ongoing trials, upcoming milestones and much more. Published ...

Chennai: A new AI-enabled deep brain stimulation (DBS) device, one that can read brain signals and adjust itself, will be ...

Theravance Biopharma, Inc. (NASDAQ: TBPH) today announced that it will host a virtual key opinion leader (KOL) investor event on Monday, December 8, 2025 at 10:30 AM ET. To register, click here.

Rare diseases reveal that our sense of identity rests on fragile biological infrastructure, much of it operating outside ...

Alterity Therapeutics’ phase II study of its lead compound ATH434 in multiple system atrophy (MSA) has been featured in an ...

A school community is rallying behind a former teacher who has been diagnosed with a rare and life-limiting condition ...

Detailed price information for Alterity Therapeutics Limited (PRNAF) from The Globe and Mail including charting and trades.

Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today ...

Ionis Pharmaceuticals Inc. ((IONS)) announced an update on their ongoing clinical study. Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert ...

A noninvasive MRI technique that measures volumetric changes in paraspinal muscles could transform how doctors assess nerve damage in the cervical spine, which helps guide more precise treatment ...

Geographic atrophy due to age-related macular degeneration (AMD) is the leading cause of irreversible blindness and affects more than 5 million persons worldwide. No therapies to restore vision in ...

The Hong Kong University of Science and Technology (HKUST) today launched SmartPath, a comprehensive artificial intelligence (AI) system designed to transform the entire pathology workflow for cancer ...